av/affimed--big.svg

NASDAQ:AFMD

Affimed N.V.

  • Stock

1.10

+10.55%

0.97

USD last updated 15/08 02:20:07

Last Close

0.13

14/05 22:29

Market Cap

77.05M

Beta: 2.51

Volume Today

164.89K

Avg: 923.39K

PE Ratio

−0.59

PFCF: −0.61

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -2-1.5-1-0.52018-11-072020-08-112022-03-312024-03-282024-08-22

    Revenue (Estimate*)

    10M20M30M40M50M60M2018-11-072020-08-112022-03-312024-03-282024-08-22

    *Estimate based on analyst consensus